XLO News and Press, Xilio Therapeutics Inc. From 12/02/21

Xilio Therapeutics (NASDAQ:XLO): Q3 GAAP EPS of -$21.27. Press Release Cash and cash equivalents were $99.8 million as of September 30, 2021, compared to $19.2 million as of December 31, 2020. Cash and cash equivalents as of September 30, 2021 do not include $116.3 million in estimated net pr...

Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4 Successfully Closed IPO in Fourth Quarter of 2021, Raising Approximately ...

Extending the three consecutive sessions of losses, the shares of Xilio Therapeutics (XLO -24.0%) have recorded the biggest one-day loss to reach their lowest level since the company IPO last month. The clinical-stage oncology company sought $75.6M in gross proceeds with its IPO for 5.4M shar...

Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced data from preclinical studies of XTX301, an engineered tumor-se...